Developability assessment workflows to de-risk biopharmaceutical development

Developability of Biotherapeutics: Computational Approaches

Volumn , Issue , 2015, Pages 221-289

  Zurdo, Jesús ^a   Arnell, Andreas ^a   Obrezanova, Olga ^a   Smith, Noel ^a   Gallagher, Thomas R A ^a   de la Cuesta, Ramón Gómez ^a   Locwin, Ben ^b  

^a LONZA AG   (Switzerland)

^b Lonza Biologics Inc Portsmouth   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPHARMACEUTICAL DEVELOPMENT; CLINICAL DEVELOPMENT; DEVELOPABILITY; DRUG CANDIDATES; DRUG DEVELOPMENT; RE-TURN-ON; THERAPEUTIC TREATMENTS; WORK-FLOWS;

RISK ASSESSMENT;

EID: 85013945781     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b19023     Document Type: Chapter

References (137)

1. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. (2014). Clinical devel¬opment success rates for investigational drugs. Nat Biotechnol 32: 40-51.
2. Kola I, Landis J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3: 711-715.
3. Arrowsmith J, Miller P. (2013). Trial watch: Phase II and phase III attrition rates 2011-2012. Nat Rev Drug Discov 12: 569.
4. Sacks LV, Shamsuddin HH, Yasinskaya YI, Bouri K, Lanthier ML, Sherman RE. (2014). Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012. JAMA 311: 378-384.
5. Tversky A, Kahneman D. (1974). Judgment under uncertainty: Heuristics and biases. Science 185: 1124-1131.
6. Juran JM, Godfrey AB. (1999). Quality Handbook. New York: McGraw-Hill.
7. Schiffauerova A, Thomson V. (2006). A review of research on cost of quality models and best practices. Int J Qual Reliab Manag 23: 647-669.
8. Kozlowski S, Swann P. (2006). Current and future issues in the manufacturing and development of monoclonal antibodies. Adv Drug Deliv Rev 58: 707-722.
9. Defeo J, Juran JM. (2010). Quality Handbook: The Complete Guide to Performance Excellence. 6th ed. New York: McGraw Hill Professional.
10. Zurdo J. (2013). Developability assessment as an early de-risking tool for biopharma¬ceutical development. Pharm Bioprocess 1: 29-50.
11. Zurdo J. (2013). Developability. Surviving the valley of death. EBR 195: 50-54.
12. Rathore AS, Mhatre R. (2009). Quality by Design for Biopharmaceuticals: Principles and Case Studies. Hoboken, NJ: John Wiley & Sons.
13. Zurdo J, Michael R, Stallwood Y, Hedman K, Aastrup T. (2011). Improving the devel¬opability of biopharmaceuticals. Innov Pharm Technol 37: 34-40.
14. Mazza CB, Sukumar N, Breneman CM, Cramer SM. (2001). Prediction of protein retention in ion-exchange systems using molecular descriptors obtained from crystal structure. Anal Chem 73: 5457-5461.
15. Dismer F, Hubbuch J. (2010). 3D structure-based protein retention prediction for ion-exchange chromatography. J Chromatogr A 1217: 1343-1353.
16. Satish H, Angell N, Lowe D, Shah A, Bishop S. (2013). Application of biophysics to early developability assessment of therapeutic candidates and its application to enhance developability properties. In Narhi LO, ed., Biophysics for Therapeutic Protein Development. New York: Springer, pp. 127-146.
17. Bermudez O, Forciniti D. (2004). Aggregation and denaturation of antibodies: A cap¬illary electrophoresis, dynamic light scattering, and aqueous two-phase partitioning study. J Chromatogr B Analyt Technol Biomed Life Sci 807: 17-24.
18. Mahler HC, Friess W, Grauschopf U, Kiese S. (2009). Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci 98: 2909-2934.
19. Johnson DH, Parupudi A, Wilson WW, DeLucas LJ. (2009). High-throughput self-interaction chromatography: Applications in protein formulation prediction. Pharm Res 26: 296-305.
20. He F, Becker GW, Litowski JR, Narhi LO, Brems DN, Razinkov VI. (2010). High-throughput dynamic light scattering method for measuring viscosity of concentrated protein solutions. Anal Biochem 399: 141-143.
21. Connolly BD, Petry C, Yadav S, Demeule B, Ciaccio N, Moore JM, Shire SJ, Gokarn YR. (2012). Weak interactions govern the viscosity of concentrated antibody solutions: High-throughput analysis using the diffusion interaction parameter. Biophys J 103: 69-78.
22. Neergaard MS, Kalonia DS, Parshad H, Nielsen AD, Moller EH, van de Weert M. (2013). Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass: Prediction of viscosity through protein-protein interac¬tion measurements. Eur J Pharm Sci 49: 400-410.
23. Wagner M, Reiche K, Blume A, Garidel P. (2013). Viscosity measurements of antibody solutions by photon correlation spectroscopy: An indirect approach-limitations and applicability for high-concentration liquid protein solutions. Pharm Dev Technol 18: 963-970.
24. Meek-Brown G, Qureshi R, Myers R, Patel B, Berrt P, Rawal S, Aldana S, Barredo M, Higgins L, Alam I. (2013). Development of a high throughput platform to assess prod¬uct quality in mammalian cells producing custom and biosimilar monoclonal antibod¬ies. Presented at International Bioanalytical Congress, Berlin, September 12.
25. Cromwell ME, Hilario E, Jacobson F. (2006). Protein aggregation and bioprocessing. AAPS J 8: E572-E579.
26. Vazquez-Rey M, Lang DA. (2011). Aggregates in monoclonal antibody manufacturing processes. Biotechnol Bioeng 108: 1494-1508.
27. Sniegowski M, Mandava N, Kahook MY. (2010). Sustained intraocular pressure eleva¬tion after intravitreal injection of bevacizumab and ranibizumab associated with trabe¬culitis. Open Ophthalmol J 4: 28-29.
28. Chirino AJ, Ary ML, Marshall SA. (2004). Minimizing the immunogenicity of protein therapeutics. Drug Discov Today 9: 82-90.
29. Rosenberg AS. (2006). Effects of protein aggregates: An immunologic perspective. AAPS J 8: E501-E507.
30. Schellekens H, Jiskoot W. (2006). Erythropoietin-associated PRCA: Still an unsolved mystery. J Immunotoxicol 3: 123-130.
31. Seidl A, Hainzl O, Richter M, Fischer R, Bohm S, Deutel B, Hartinger M, Windisch J, Casadevall N, London GM, Macdougall I. (2012). Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res 29: 1454-1467.
32. MacDougall IC, Roger SD, de Francisco A, Goldsmith DJ, Schellekens H, Ebbers H, Jelkmann W, London G, Casadevall N, Horl WH, Kemeny DM, Pollock C. (2012). Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiv¬ing erythropoiesis-stimulating agents: New insights. Kidney Int 81: 727-732.
33. Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W. (2004). Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 21: 897-903.
34. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA. (2008). Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 358: 1109-1117.
35. Philo JS, Arakawa T. (2009). Mechanisms of protein aggregation. Curr Pharm Biotechnol 10: 348-351.
36. Gsponer J, Vendruscolo M. (2006). Theoretical approaches to protein aggregation. Protein Pept Lett 13: 287-293.
37. Caflisch A. (2006). Computational models for the prediction of polypeptide aggrega¬tion propensity. Curr Opin Chem Biol 10: 437-444.
38. Kumar S, Wang X, Singh SK. (2010). Identification and impact of aggregation-prone regions in proteins and therapeutic monoclonal antibodies. In Wang W, Roberts CJ, eds., Aggregation of Therapeutic Proteins. Hoboken, NJ: John Wiley & Sons, pp. 103-118.
39. Buck PM, Kumar S, Wang X, Agrawal NJ, Trout BL, Singh SK. (2012). Computational methods to predict therapeutic protein aggregation. Methods Mol Biol 899: 425-451.
40. Chiti F, Stefani M, Taddei N, Ramponi G, Dobson CM. (2003). Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424: 805-808.
41. Dubay KF, Pawar AP, Chiti F, Zurdo J, Dobson CM, Vendruscolo M. (2004). Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains. J Mol Biol 341: 1317-1326.
42. Tartaglia GG, Pawar AP, Campioni S, Dobson CM, Chiti F, Vendruscolo M. (2008). Prediction of aggregation-prone regions in structured proteins. J Mol Biol 380: 425-436.
43. Fowler SB, Poon S, Muff R, Chiti F, Dobson CM, Zurdo J. (2005). Rational design of aggregation-resistant bioactive peptides: Reengineering human calcitonin. Proc Natl Acad Sci USA 102: 10105-10110.
44. Michael R, Stallwood Y, Jimenez JL, Demir M, Arnell A, Zurdo J. (2008). Protein engineering to reduce antibody aggregation. CHI Antibody Europe. Lisbon, Portugal.
45. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. (2009). Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci USA 106: 11937-11942.
46. Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL. (2012). Developability index: A rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci 101: 102-115.
47. Perchiacca JM, Ladiwala AR, Bhattacharya M, Tessier PM. (2012). Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. Protein Eng Des Sel 25: 591-601.
48. Chaudhri A, Zarraga IE, Kamerzell TJ, Brandt JP, Patapoff TW, Shire SJ, Voth GA. (2012). Coarse-grained modeling of the self-association of therapeutic monoclonal antibodies. J Phys Chem B 116: 8045-8057.
49. Yadav S, Liu J, Shire SJ, Kalonia DS. (2010). Specific interactions in high concentration antibody solutions resulting in high viscosity. J Pharm Sci 99: 1152-1168.
50. Wang X, Das TK, Singh SK, Kumar S. (2009). Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies. MAbs 1: 254-267.
51. Wang X, Singh SK, Kumar S. (2010). Potential aggregation-prone regions in comple¬mentarity-determining regions of antibodies and their contribution towards antigen recognition: A computational analysis. Pharm Res 27: 1512-1529.
52. Wu SJ, Luo J, O’Neil KT, Kang J, Lacy ER, Canziani G, Baker A, Huang M, Tang QM, Raju TS, Jacobs SA, Teplyakov A, Gilliland GL, Feng Y. (2010). Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng Des Sel 23: 643-651.
53. Conley GP, Viswanathan M, Hou Y, Rank DL, Lindberg AP, Cramer SM, Ladner RC, Nixon AE, Chen J. (2011). Evaluation of protein engineering and process optimiza¬tion approaches to enhance antibody drug manufacturability. Biotechnol Bioeng 108: 2634-2644.
54. Ewert S, Huber T, Honegger A, Pluckthun A. (2003). Biophysical properties of human antibody variable domains. J Mol Biol 325: 531-553.
55. Ewert S, Cambillau C, Conrath K, Pluckthun A. (2002). Biophysical properties of cam¬elid V(HH) domains compared to those of human V(H)3 domains. Biochemistry 41: 3628-3636.
56. Wang N, Smith WF, Miller BR, Aivazian D, Lugovskoy AA, Reff ME, Glaser SM, Croner LJ, Demarest SJ. (2009). Conserved amino acid networks involved in antibody variable domain interactions. Proteins 76: 99-114.
57. Obrezanova O, Arnell A, Gomez de la Cuesta R, Berthelot ME, Gallagher TRA, Zurdo J, Stallwood Y. (2015). Aggregation risk prediction for antibodies and its application to biotherapeutic development. MAbs, 7: 352-363.
58. Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. (2008). Heterogeneity of mono¬clonal antibodies. J Pharm Sci 97: 2426-2447.
59. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. (2010). Stability of protein pharmaceuticals: An update. Pharm Res 27: 544-575.
60. Buchanan A, Clementel V, Woods R, Harn N, Bowen MA, Mo W, Popovic B, Bishop SM, Dall’acqua W, Minter R, Jermutus L, Bedian V. (2013). Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression. MAbs 5: 255-262.
61. Robinson NE, Robinson AB. (2001). Molecular clocks. Proc Natl Acad Sci USA 98: 944-949.
62. Harris RJ, Kabakoff B, Macchi FD, Shen FJ, Kwong M, Andya JD, Shire SJ, Bjork N, Totpal K, Chen AB. (2001). Identification of multiple sources of charge heterogeneity in a recombinant antibody. J Chromatogr B Biomed Sci Appl 752: 233-245.
63. Shire SJ. (2009). Formulation and manufacturability of biologics. Curr Opin Biotechnol 20: 708-714.
64. Yang X, Xu W, Dukleska S, Benchaar S, Mengisen S, Antochshuk V, Cheung J, Mann L, Babadjanova Z, Rowand J, Gunawan R, McCampbell A, Beaumont M, Meininger D, Richardson D, Ambrogelly A. (2013). Developability studies before initiation of process development: Improving manufacturability of monoclonal antibodies. MAbs 5: 787-794.
65. Haberger M, Bomans K, Diepold K, Hook M, Gassner J, Schlothauer T, Zwick A, Spick C, Kepert JF, Hienz B, Wiedmann M, Beck H, Metzger P, Molhoj M, Knoblich C, Grauschopf U, Reusch D, Bulau P. (2014). Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes. MAbs 6: 327-339.
66. Li H, d’Anjou M. (2009). Pharmacological significance of glycosylation in therapeutic proteins. Curr Opin Biotechnol 20: 678-684.
67. van Beers MM, Bardor M. (2012). Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnol J 7: 1484.
68. Walsh G. (2010). Post-translational modifications of protein biopharmaceuticals. Drug Discov Today 15: 773-780.
69. Zurdo J. (2005). Polypeptide models to understand misfolding and amyloidogenesis and their relevance in protein design and therapeutics. Protein Pept Lett 12: 171-188.
70. Arnell A, Jimenez JL, Michael R, Stallwood Y, Zurdo J, inventors. (2011). Variant immu¬noglobulins with improved manufacturability. U.S. Patent Application WO2011021009 A1.
71. Pybus LP, James DC, Dean G, Slidel T, Hardman C, Smith A, Daramola O, Field R. (2014). Predicting the expression of recombinant monoclonal antibodies in Chinese hamster ovary cells based on sequence features of the CDR3 domain. Biotechnol Prog 30: 188-197.
72. Condino AA, Fidanza S, Hoffenberg EJ. (2005). A home infliximab infusion program. J Pediatr Gastroenterol Nutr 40: 67-69.
73. Grainger DW. (2004). Controlled-release and local delivery of therapeutic antibodies. Expert Opin Biol Ther 4: 1029-1044.
74. Narasimhan C, Mach H, Shameem M. (2012). High-dose monoclonal antibodies via the subcutaneous route: Challenges and technical solutions, an industry perspective. Ther Deliv 3: 889-900.
75. Shire SJ, Shahrokh Z, Liu J. (2004). Challenges in the development of high protein concentration formulations. J Pharm Sci 93: 1390-1402.
76. Birch JR, Racher AJ. (2006). Antibody production. Adv Drug Deliv Rev 58: 671-685.
77. Banks DD, Latypov RF, Ketchem RR, Woodard J, Scavezze JL, Siska CC, Razinkov VI. (2012). Native-state solubility and transfer free energy as predictive tools for select¬ing excipients to include in protein formulation development studies. J Pharm Sci 101: 2720-2732.
78. Lehermayr C, Mahler HC, Mader K, Fischer S. (2011). Assessment of net charge and protein-protein interactions of different monoclonal antibodies. J Pharm Sci 100: 2551-2562.
79. Maddux NR, Joshi SB, Volkin DB, Ralston JP, Middaugh CR. (2011). Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J Pharm Sci 100: 4171-4197.
80. Clarke JB. (2010). Mechanisms of adverse drug reactions to biologics. Handb Exp Pharmacol 196: 453-474.
81. Scherer K, Spoerl D, Bircher AJ. (2010). Adverse drug reactions to biologics. J Dtsch Dermatol Ges 8: 411-426.
82. Rosenberg AS, Worobec A. (2004). A risk-based approach to immunogenicity con¬cerns of therapeutic protein products. Part 2: Considering host-specific and product-specific factors impacting immunogenicity. Biopharm Int 17: 34-42.
83. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018-1028.
84. Selewski DT, Shah GV, Segal BM, Rajdev PA, Mukherji SK. (2010). Natalizumab (Tysabri). AJNR Am J Neuroradiol 31: 1588-1590.
85. Miki H, Okamoto A, Ishigaki K, Sasaki O, Sumitomo S, Fujio K, Yamamoto K. (2011). Cardiopulmonary arrest after severe anaphylactic reaction to second infusion of inflix¬imab in a patient with ankylosing spondylitis. J Rheumatol 38: 1220.
86. Schellekens H. (2002). Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1: 457-462.
87. Committee for Medicinal Products for Human Use (CHMP). (2007). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. EMA CHMP. EMEA/CHMP/BMWP/14327/2006.
88. Committee for Medicinal Products for Human Use CHMP. (2009). Concept paper on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. EMA CHMP. EMEA/CHMP/BMWP/114720/2009.
89. Buttel IC, Chamberlain P, Chowers Y, Ehmann F, Greinacher A, Jefferis R, Kramer D, Kropshofer H, Lloyd P, Lubiniecki A, Krause R, Mire-Sluis A, Platts-Mills T, Ragheb JA, Reipert BM, Schellekens H, Seitz R, Stas P, Subramanyam M, Thorpe R, Trouvin JH, Weise M, Windisch J, Schneider CK. (2011). Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 39: 100-109.
90. Parenky A, Myler H, Amaravadi L, Bechtold-Peters K, Rosenberg A, Kirshner S, Quarmby V. (2014). New FDA draft guidance on immunogenicity. AAPS J 16: 499-503.
91. Van Walle I, Gansemans Y, Parren PW, Stas P, Lasters I. (2007). Immunogenicity screening in protein drug development. Expert Opin Biol Ther 7: 405-418.
92. Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. (2013). T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clin Immunol 149: 534-555.
93. Rohn TA, Reitz A, Paschen A, Nguyen XD, Schadendorf D, Vogt AB, Kropshofer H. (2005). A novel strategy for the discovery of MHC class II-restricted tumor anti¬gens: Identification of a melanotransferrin helper T-cell epitope. Cancer Res 65: 10068-10078.
94. Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, Hey A, Muller PY, Frings W, Sims J. (2010). Safety and immunotoxicity assessment of immunomodu¬latory monoclonal antibodies. MAbs 2: 233-255.
95. Rombach-Riegraf V, Karle AC, Wolf B, Sorde L, Koepke S, Gottlieb S, Krieg J, Djidja MC, Baban A, Spindeldreher S, Koulov AV, Kiessling A. (2014). Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimu¬late adaptive T-cell responses in vitro. PLoS One 9: e86322.
96. Findlay L, Eastwood D, Ball C, Robinson CJ, Bird C, Wadhwa M, Thorpe SJ, Thorpe R, Stebbings R, Poole S. (2011). Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy. J Immunol Methods 371: 134-142.
97. Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, Kuchel GA. (2008). ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci 63: 879-884.
98. Cupedo T, Stroock A, Coles M. (2012). Application of tissue engineering to the immune system: Development of artificial lymph nodes. Front Immunol 3: 1-6.
99. Holland MC, Wurthner JU, Morley PJ, Birchler MA, Lambert J, Albayaty M, Serone AP, Wilson R, Chen Y, Forrest RM, Cordy JC, Lipson DA, Bayliffe AI. (2013). Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-alpha recep¬tor 1. J Clin Immunol 33: 1192-1203.
100. Jahnmatz M, Kesa G, Netterlid E, Buisman AM, Thorstensson R, Ahlborg N. (2013). Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell responses. J Immunol Methods 391: 50-59.
101. Weiss WF, Young TM, Roberts CJ. (2009). Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. J Pharm Sci 98: 1246-1277.
102. Hermeling S, Schellekens H, Crommelin DJ, Jiskoot W. (2003). Micelle-associated protein in epoetin formulations: A risk factor for immunogenicity? Pharm Res 20: 1903-1907.
103. Creeke PI, Farrell RA. (2013). Clinical testing for neutralizing antibodies to interferon-beta in multiple sclerosis. Ther Adv Neurol Disord 6: 3-17.
104. Kumar S, Singh SK, Wang X, Rup B, Gill D. (2011). Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggre¬gation-prone regions. Pharm Res 28: 949-961.
105. Kumar S, Mitchell MA, Rup B, Singh SK. (2012). Relationship between potential aggregation-prone regions and HLA-DR-binding T-cell immune epitopes: Implications for rational design of novel and follow-on therapeutic antibodies. J Pharm Sci 101: 2686-2701.
106. Frigault MJ, June CH. (2011). Predicting cytokine storms: It’s about density. Blood 118: 6724-6726.
107. Bailey L, Moreno L, Manigold T, Krasniqi S, Kropshofer H, Hinton H, Singer T, Suter L, Hansel TT, Mitchell JA. (2013). A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies. J Pharmacol Toxicol Methods 68: 231-239.
108. Locwin B. (2013). Quality risk assessment and management strategies for biopharma¬ceutical companies. Bioprocess Int 11: 52-57.
109. Sober E. (1981). The principle of parsimony. Brit J Phil Sci 32: 145-156.
110. Ishikawa K, Oftus JH. (1990). Introduction to quality control. Chapman & Hall, London, UK.
111. Miller GA. (1956). The magical number seven, plus or minus two: Some limits on our capacity for processing information. Psychol Rev 63: 81-97.
112. Czitrom V, Spagon PD. (1997). Statistical case studies for industrial process improve¬ment. SIAM, Philadelphia.
113. Hann MM, Keseru GM. (2012). Finding the sweet spot: The role of nature and nurture in medicinal chemistry. Nat Rev Drug Discov 11: 355-365.
114. Segall MD. (2012). Multi-parameter optimization: Identifying high quality compounds with a balance of properties. Curr Pharm Des 18: 1292-1310.
115. Nicolaou CA, Brown N. (2013). Multi-objective optimization methods in drug design. Drug Discov Today Technol 10: e427-e435.
116. Ekins S, Honeycutt JD, Metz JT. (2010). Evolving molecules using multi-objective opti¬mization: Applying to ADME/Tox. Drug Discov Today 15: 451-460.
117. Segall MD, Champness E, Obrezanova O, Leeding C. (2009). Beyond profiling: Using ADMET models to guide decisions. Chem Biodivers 6: 2144-2151.
118. CMC Biotech Working Group. (2009). A-Mab: A case study in bioprocess develop¬ment. Version 2.1. http://c.ymcdn.com/sites/www.casss.org/resource/resmgr/imported/A-Mab_Case_Study_Version_2-1.pdf.
119. Ponsel D, Neugebauer J, Ladetzki-Baehs K, Tissot K. (2011). High affinity, develop¬ability and functional size: The holy grail of combinatorial antibody library generation. Molecules 16: 3675-3700.
120. Tiller T, Schuster I, Deppe D, Siegers K, Strohner R, Herrmann T, Berenguer M, Poujol D, Stehle J, Stark Y, Hessling M, Daubert D, Felderer K, Kaden S, Kolln J, Enzelberger M, Urlinger S. (2013). A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties. MAbs 5: 445-470.
121. Steinwand M, Droste P, Frenzel A, Hust M, Dubel S, Schirrmann T. (2013). The influ¬ence of antibody fragment format on phage display based affinity maturation of IgG. MAbs 6: 204-218.
122. Lonberg N. (2005). Human antibodies from transgenic animals. Nat Biotechnol 23: 1117-1125.
123. Höidén-Guthenberg I, Jonsson A, Ståhl S, Friedman M, Wållberg H, Bass T, Tolmachev V, Frejd F, Ekblad C. (2012). Combining Affibody® molecules and the Albumod™ technology to create long acting multispecific protein therapeutics. MAbs 4: 14-16.
124. Sampei Z, Igawa T, Soeda T, Okuyama-Nishida Y, Moriyama C, Wakabayashi T, Tanaka E, Muto A, Kojima T, Kitazawa T, Yoshihashi K, Harada A, Funaki M, Haraya K, Tachibana T, Suzuki S, Esaki K, Nabuchi Y, Hattori K. (2013). Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One 8: e57479.
125. Zurdo J, Arnell A, Obrezanova O, Smith N, Gómez de la Cuesta R, Gallagher TRA, Michael R, Stallwood Y, Ekblad C, Höidén-Guthenberg I. (2015). Early implementa¬tion of QbD in biopharmaceutical development: A practical example. Biomed Res Int, Vol. 2015, Article ID 605 427, 2015. doi:10.1155/2015/605427.
126. Frejd FY. (2012). Half-life extension by binding to albumin through an albumin binding domain. In Kontermann RE, ed., Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives. Weinheim: Wiley-Blackwell, pp. 269-283.
127. Strohl WR, Strohl LM. (2012). Therapeutic Antibody Engineering. Cambridge, UK: Woodhead Publishing.
128. Jonsson A, Dogan J, Herne N, Abrahmsen L, Nygren PA. (2008). Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng Des Sel 21: 515-527.
129. Goetsch L, Haeuw JF, Champion T, Lacheny C, N’Guyen T, Beck A, Corvaia N. (2003). Identification of B- and T-cell epitopes of BB, a carrier protein derived from the G protein of Streptococcus strain G148. Clin Diagn Lab Immunol 10: 125-132.
130. Fan ZC, Shan L, Goldsteen BZ, Guddat LW, Thakur A, Landolfi NF, Co MS, Vasquez M, Queen C, Ramsland PA, Edmundson AB. (1999). Comparison of the three-dimen¬sional structures of a humanized and a chimeric Fab of an anti-gamma-interferon anti¬body. J Mol Recognit 12: 19-32.
131. Singh SK, Afonina N, Awwad M, Bechtold-Peters K, Blue JT, Chou D, Cromwell M, Krause HJ, Mahler HC, Meyer BK, Narhi L, Nesta DP, Spitznagel T. (2010). An indus¬try perspective on the monitoring of subvisible particles as a quality attribute for pro¬tein therapeutics. J Pharm Sci 99: 3302-3321.
132. Rathore AS, Winkle H. (2009). Quality by design for biopharmaceuticals. Nat Biotechnol 27: 26-34.
133. Gu J, Ghayur T. (2010). Rationale and development of multispecific antibody drugs. Expert Rev Clin Pharm 3: 491-508.
134. Kaitin KI. (2010). Deconstructing the drug development process: The new face of inno¬vation. Clin Pharmacol Ther 87: 356-361.
135. Rees H. (2011). Supply Chain Management in the Drug Industry: Delivering Patient Value for Pharmaceuticals and Biologics. Hoboken, NJ: John Wiley & Sons.
136. Fraser J, Kerboul G. (2012). A holistic approach to pharmaceutical manufacturing: Product lifecycle management support for high yield processes to make safe and effec¬tive drugs. Pharma Eng 32: 1-5.
137. Zhu J. (2012). Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv 30: 1158-1170.